Recently, Pfizer's new generation of specific migraine treatment drug, Rimezepam orally disintegrating tablets, has been approved for market by the National Medical Products Administration for only 43 days. It has taken the lead in landing at the General Hospital of the People's Liberation Army of China and is currently accelerating its clinical use in major hospitals across the country, continuously issuing its first prescription to accelerate the benefits of migraine patients and help China enter a new era of specific oral targeted drugs for migraine treatment. Migraine is a common and disabling disease characterized by high incidence, high disability, and high disease burden, and has become one of the main global public health issues. Its symptoms are characterized by recurrent attacks, mostly unilateral, moderate to severe pulsatile headache, usually lasting 4-72 hours, often accompanied by symptoms such as nausea, vomiting, photophobia, and fear of sound. Long term recurrent attacks lead to serious health losses, decreased quality of life, and loss of productivity. Meanwhile, migraines are often accompanied by various complications, such as anxiety, depression, cerebrovascular disease, sleep disorders, etc., causing a significant burden on the disease. Data shows that the cumulative loss of healthy lifespan caused by disabilities caused by headaches worldwide is 46.6 million person years, of which 88.2% is attributed to migraines. From a gender perspective, migraines tend to favor females, with a male to female ratio of 1:2.2, with females aged 15-49 ranking first. However, due to the lack of specific drugs in the past, the treatment of migraine has significant limitations in efficacy and safety. Not only is the treatment response insufficient and symptoms prone to recurrence, but patients also face the risk of chronic headache and drug overuse induced headaches that may be caused by long-term use of painkillers, as well as contraindications for cardiovascular disease patients. According to the widely recognized view, migraine is classified as a brain dysfunction disease rather than a vascular disease. Migraine is related to the trigeminal nerve and is mainly caused by neurogenic inflammation of the meninges. Neuromediators such as calcitonin gene related peptide (CGRP), substance P, vasoactive intestinal peptide, and pituitary adenosine monopeptide (PACAP) The release of other mediators leads to the exudation of inflammatory factors, which in turn triggers a painful response. This kind of pain, in turn, reactivates the trigeminal nerve, forming a vicious cycle known as the trigeminal neurovascular reflex Introduction by Yu Shengyuan, Director of the Department of Neurology at the General Hospital of the People's Liberation Army and President of the Neurologist Branch of the Chinese Medical Association. Yu Shengyuan stated that innovative drugs targeting calcitonin gene related peptide (CGRP), such as remizepam, can alleviate migraine symptoms by blocking the binding of the aforementioned neurotransmitters and receptors. CGRP is a proactive challenge initiated by humans towards headache - to develop corresponding drugs based on the mechanism of action of CGRP for intervention and treatment. As the world's first and only calcitonin gene related peptide (CGRP) receptor antagonist using patented orally disintegrating tablet technology, remizepam has shown positive results in key trials in China, effectively blocking key pathways related to migraine onset and rapidly and continuously relieving headaches and related accompanying symptoms. In addition, Rimezepam orally disintegrating tablets have been recommended by migraine guidelines in the United States, Europe, and China. With the first landing at the General Hospital of the People's Liberation Army of China, the new generation of migraines